🇺🇸 FDA
Patent

US 11071749

Oligonucleotide analogues targeting human LMNA

granted A61KA61K31/713A61K47/6455

Quick answer

US patent 11071749 (Oligonucleotide analogues targeting human LMNA) held by Sarepta Therapeutics, Inc. expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/713, A61K47/6455, A61P, A61P43/00